Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies.

[1]  C. Loo.  Manual of Benirschke and Kaufmann’s Pathology of the Human Placenta , 2006 .

[2]  L. Poston,et al.  The placental bed in pregnancies complicated by primary antiphospholipid syndrome. , 2006, Placenta.

[3]  L. Myatt.  Placental adaptive responses and fetal programming , 2006, The Journal of physiology.

[4]  J. Salmon,et al.  The complement system in the pathophysiology of pregnancy. , 2006, Molecular immunology.

[5]  R. Derksen,et al.  Pathophysiology of the antiphospholipid syndrome , 2005, Journal of thrombosis and haemostasis : JTH.

[6]  G. Girardi.  Heparin treatment in pregnancy loss: Potential therapeutic benefits beyond anticoagulation. , 2005, Journal of reproductive immunology.

[7]  J. Thurman,et al.  A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. , 2005, Molecular immunology.

[8]  J. Salmon,et al.  Heparin prevents antiphospholipid antibody–induced fetal loss by inhibiting complement activation , 2004, Nature Medicine.

[9]  M. Khamashta,et al.  Management of the obstetric antiphospholipid syndrome. , 2004, Arthritis and rheumatism.

[10]  S. Richards,et al.  Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. , 2004, The New England journal of medicine.

[11]  B. Morgan,et al.  The Many Faces of the Membrane Regulators of Complement , 2004 .

[12]  J. Szebeni.  The complement system : novel roles in health and disease , 2004 .

[13]  J. Lambris,et al.  Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. , 2003, The Journal of clinical investigation.

[14]  V. Holers,et al.  Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis , 2002, Annals of the rheumatic diseases.

[15]  Xiaowei Liu,et al.  Edinburgh Research Explorer Complement C3 activation is required for antiphospholipid antibody-induced fetal loss , 2022 .

[16]  T. Nagasawa,et al.  Inhibition of complement‐mediated haemolysis in paroxysmal nocturnal haemoglobinuria by heparin or low‐molecular weight heparin , 2000, British journal of haematology.

[17]  M. Peterson,et al.  Placental pathology in systemic lupus erythematosus: a prospective study. , 1998, American journal of obstetrics and gynecology.

[18]  C. Salafia,et al.  Placental pathology in systemic lupus erythematosus and phospholipid antibody syndrome. , 1997, Scandinavian journal of rheumatology. Supplement.

[19]  J. Rand,et al.  Pregnancy loss in the antiphospholipid-antibody syndrome--a possible thrombogenic mechanism. , 1997, The New England journal of medicine.

[20]  J. Lasala,et al.  Activation of cultured vascular endothelial cells by antiphospholipid antibodies. , 1995, The Journal of clinical investigation.

[21]  F. Nicoletti,et al.  Placental Thrombosis and Fetal Loss After Passive Transfer of Mouse Lupus Monoclonal or Human Polyclonal Anti‐Cardiolipin Antibodies in Pregnant Naive BALB/c Mice , 1995, Scandinavian journal of immunology.

[22]  E. Harris,et al.  The antiphospholipid syndrome , 1995, Clinical reviews in allergy & immunology.

[23]  J. Weiler,et al.  Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum. , 1994, Immunopharmacology.

[24]  R. Derksen,et al.  Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. , 1991, European journal of obstetrics, gynecology, and reproductive biology.

[25]  Y. Shoenfeld,et al.  Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. Mitchell,et al.  Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss. , 1990, American journal of obstetrics and gynecology.

[27]  M. Kazatchkine,et al.  Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. , 1981, The Journal of clinical investigation.

[28]  E. E. Ecker,et al.  Anticomplementary Power of Heparin , 1929 .